Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
10/27/2022* -- Results Q3 2022 -- 0.03 --
10/27/2022* 08:00 EST Earnings Call Q3 2022 -- -- --
07/27/2022 08:00 EST Earnings Call Q2 2022 -- -- --
07/27/2022 -- Results Q2 2022 0.06 0.05 26.72%
04/27/2022 -- Results Q1 2022 -- 0.03 --
04/27/2022 08:00 EST Earnings Call Q1 2022 -- -- --
02/16/2022 -- Results Q4 2021 0.23 0.13 72.50%
02/16/2022 08:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 10/27/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 07/27/2022
Beat/Miss Upgrade
Return Since -20.88%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
URL https://www.alkermes.com
Investor Relations URL https://investor.alkermes.com
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Small Cap/Growth
Next Earnings Release Oct. 27, 2022 (est.)
Last Earnings Release Jul. 27, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
35.55%
-29.98%
-1.53%
-46.08%
-30.87%
-2.21%
16.59%
-5.33%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-22.58%
-14.15%
-22.43%
23.50%
-7.94%
20.43%
10.56%
-22.81%
-0.64%
-13.18%
-42.14%
5.59%
-55.08%
35.65%
-11.92%
-10.96%
-5.06%
48.92%
-57.23%
-13.04%
-44.44%
36.00%
16.91%
-23.27%
87.70%
--
--
--
--
-10.18%
-78.02%
-60.38%
-71.92%
As of September 27, 2022.

Profile

Edit
Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
URL https://www.alkermes.com
Investor Relations URL https://investor.alkermes.com
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Small Cap/Growth
Next Earnings Release Oct. 27, 2022 (est.)
Last Earnings Release Jul. 27, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
DDDCX 11.58M USD 5.17%
PBE 5.921M USD 2.67%
SBIO 1.990M USD 2.06%
DOPIX 7.838M USD 1.99%
HRSGX 14.85M USD 1.76%
BMEZ 34.65M USD 1.63%
GTCSX 17.01M USD 1.44%
HSPCX 11.87M USD 1.34%
DLRHX 10.83M USD 1.24%
XBI 68.08M USD 1.07%
LABU 7.251M USD 0.87%
GSSC 1.124M USD 0.27%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ALKS Tweets